Brokerages Set Heron Therapeutics, Inc. (NASDAQ:HRTX) PT at $4.50

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been given an average recommendation of “Hold” by the five brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $4.50.

Several equities research analysts have recently commented on the company. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Wednesday, October 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $1.35 on Wednesday. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89. The stock has a market capitalization of $247.54 million, a PE ratio of -15.00 and a beta of 1.34. The firm’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.46. Heron Therapeutics has a twelve month low of $1.00 and a twelve month high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The company had revenue of $38.21 million for the quarter, compared to the consensus estimate of $39.03 million. Equities research analysts expect that Heron Therapeutics will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Heron Therapeutics

Several large investors have recently added to or reduced their stakes in HRTX. PKS Advisory Services LLC bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $25,000. R Squared Ltd purchased a new position in shares of Heron Therapeutics during the 2nd quarter valued at $26,000. B. Riley Wealth Advisors Inc. bought a new position in Heron Therapeutics in the 2nd quarter worth $26,000. Jones Financial Companies Lllp increased its stake in Heron Therapeutics by 5,541.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after buying an additional 23,661 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Heron Therapeutics in the 3rd quarter worth $34,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.